Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention

Non-steroidal anti-inflammatory drugs and colorectal cancer prevention.

Colorectal cancer is the second leading cause of cancer deaths in the United States. Currently, the most effective strategy available for colon cancer prevention is endoscopic screening, with polypectomy or surgical resection for advanced lesions. This intervention carries with it many concerns regarding cost, patient acceptance, and the growing burden of surveillance colonoscopies for patients...

Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers.

In recent years, several areas of biological research have increasingly supported the suggestion that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the occurrence or progression of colorectal and, to a lesser extent, oesophageal cancer or both. This suggestion is supported by consistent biochemical, pharmacological, toxicological, clinical, and epidemiological mess...

Non-steroidal anti-inflammatory drugs.

The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer

Epidemiological evidence suggests that non-steroidal anti-inflammatory drugs (NSAIDs) which act as cyclooxygenase (COX-2) inhibitors may reduce breast cancer incidence by up to 20%. These agents are often taken for pain relief by older women with osteoarthritis. Age is the major risk factor for breast cancer in women with 50% cases being diagnosed in those aged >65 years. NSAIDs reduce serum es...

Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer

Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide. Although conclusive evidence is still lacking, epidemiologic studies suggest that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) has chemopreventive properties against CRC. Similarly, regular consumption of mesalazine, a drug structurally related to NSAIDs, seems to reduce the risk of CRC in patients...